Estimation of efficiency intradermal autoserumhistaminotherapy at patients with autoimmune urticaria
Novikov D.K., Velichinskaya V.G., Konevalova N.Yu.
Vitebsk State Medical University, Vitebsk, Belarus
The purpose of the study - to test autoserumhistaminotherapy in patients with autoimmune urticaria and assess its effectiveness. To investigate subpopulation change lymphocytes and basophils under influence autoserumhistaminotherapy at patients with chronic spontaneous urticaria.
Materials and methods. 18 patients with chronic spontaneous urticaria were enrolled in the study. All patients were divided into 2 groups depending on the intradermal autoserum tests results. The first group consisted of 8 patients with autoimmune urticaria (AIC), they had the positive autoserum test results. The second group consisted of 10 patients with chronic spontaneous urticaria (HSC), they had the negative autoserum test results. All patients received pharmacotherapy if needed. Autoserumhistaminotherapy carried out by intradermal administration of autoserum with 0.01% histamine dihydrochloride solution in the several points of the body. In all patients prior to the beginning of their treatment on an empty stomach samples of blood were taken to determine the quantity and phenotype of leukocytes, the level of immunoglobulines. Phenotyping of the cells was conducted with the help of monoclonal antibodies CD19, CD23, CD3, CD4, CD25, CD8, CD69, CD203˝
Results. The positive effect of the intradermal autoserumhistaminotherapy was observed in 10-14 days of the treatment. It included the urticaria activity decreasing and the quality of life improving compared to baseline. After one year of observation, there was good treatment effect in 3 (37.5%) patients and an excellent effect (complete remission of the disease) in 4 (50.0%) patients among the patients of the first group with AIC. The second group with HSC (negative autoserum tests) had good treatment effect in 6 (60.0%) patients (p< 0,05), a complete remission of the disease in 2 (20.0%) patients after autoserumhistaminotherapy administration.
Conclusion. Intradermal autoserumhistaminotherapy is an effective method of the treatment both in patients with AIC (positive autoserum tests) and in patients with HSC (negative autoserum tests). Autoserumhistaminotherapy reduces disease activity on a scale UAS 7, improves the quality of life of the patients, reduces anti-allergic drugs using. A year after the ASGT course the drug-free remission of the disease was observed in 50.0% patients with AIC. └utoserumhistaminotherapy reduces quantity CD8 + CD25 + cytotoxic lymphocytes at their raised maintenance.